

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SP-002,Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Stamford Pharmaceuticals Announces First Patient Treated with SP-002 in Phase 2 BCC Study
Details : SP-002 is an adenovirus-based biologic producing Interferon-g, under investigation with vismodegib for locally advanced metastatic basal cell carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 11, 2024
Lead Product(s) : SP-002,Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Basal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma
Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Basal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 30, 2022
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Ronald Buckanovich
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fallopian Tube Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 13, 2022
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Ronald Buckanovich
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Basal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2017
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
Details : Erivedge is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Basal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 29, 2016
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas
Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Basal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 24, 2015
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : National Cancer Institute | GSK | Genentech | Brain Science Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Meningioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 14, 2015
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : National Cancer Institute | GSK | Genentech | Brain Science Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Odontogenic Tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 19, 2015
Lead Product(s) : Vismodegib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vismodegib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bronchiolitis Obliterans Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 13, 2015
Lead Product(s) : Vismodegib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
